INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses On Their Investment In Pomdoctor Ltd. Of Class Action Lawsuit And Upcoming Deadlines POM
| [Click here for information about joining the class action] In the weeks leading up to December 10, 2025, PomDoctor's share price surged from the initial public offering price of $4.00 to an all-time high of $6.09, despite no fundamental news from the Company that would justify such a spike. Investigations and public reports have since revealed that PomDoctor used social media to orchestrate an illicit“pump and dump” promotion scheme to defraud investors. The reports describe how impersonators claiming to be legitimate financial advisors touted PomDoctor in online forums, chat groups, and through social media posts with sensational but baseless claims to create a buying frenzy among retail investors. On December 10, 2025, PomDoctor's share price abruptly crashed by approximately 91% to $0.50. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: |
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment